Trial reportThe American journal of tropical medicine and hygiene2013
A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.
Trial report in The American journal of tropical medicine and hygiene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.The Journal of clinical investigation · 2014Trial
- Interferon-induced activation of dendritic cells and monocytes by yellow fever vaccination correlates with early antibody responses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.Journal of virology · 2024Article
- A review of the BCG vaccine and other approaches toward tuberculosis eradication.Human vaccines & immunotherapeutics · 2021Review
- Article
- Dependence of CD8 T Cell Response upon Antigen Load During Primary Infection : Analysis of Data from Yellow Fever Vaccination.Bulletin of mathematical biology · 2019Article
- Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.Journal of clinical microbiology · 2018Review
- Innate, T-, and B-Cell Responses in Acute Human Zika Patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- What Controls the Acute Viral Infection Following Yellow Fever Vaccination?Bulletin of mathematical biology · 2018Article
- CXCL13 is a plasma biomarker of germinal center activity.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.Cellular & molecular immunology · 2016Review
- Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- 17D Yellow Fever Virus Vaccine.The American journal of tropical medicine and hygiene · 2013Article
- In response.The American journal of tropical medicine and hygiene · 2013Article
- Enrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine.Tropical medicine & surgery · 2013Article
- Article
Corrections and comments
- Commented on by
- Commented on byIn response.2013
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
We evaluated whether coadministration of the yellow fever (YF) virus vaccine with human immunoglobulin (Ig) that contained YF virus-neutralizing antibodies would reduce post-vaccination viremia without compromising immunogenicity and thus, potentially mitigate YF vaccine-associated adverse events. We randomized 80 participants to receive either YF vaccine and Ig or YF vaccine and saline placebo. Participants were followed for 91 days for safety and assessments of viremia and immunogenicity. There were no differences found between the two groups in the proportion of vaccinated participants who developed viremia, seroconversion, cluster of differentiation (CD)-8(+) and CD4(+) T-cell responses, and cytokine responses. These results argue against one putative explanation for the increased reporting of YF vaccine side effects in recent years (i.e., a change in travel clinic practice after 1996 when hepatitis A prophylaxis with vaccine replaced routine use of pre-travel Ig, thus potentially removing an incidental YF vaccine-attenuating effect of anti-YF virus antibodies present in Ig).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.